Analyzing ContraFect Corporation (CFRX) and The Competition
ContraFect Corporation (NASDAQ: CFRX) is one of 93 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare ContraFect Corporation to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.
Institutional & Insider Ownership
24.5% of ContraFect Corporation shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 9.3% of ContraFect Corporation shares are owned by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for ContraFect Corporation and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ContraFect Corporation Competitors||164||544||1200||16||2.56|
ContraFect Corporation presently has a consensus target price of $5.00, suggesting a potential upside of 430.90%. As a group, “Biotechnology” companies have a potential upside of 52.02%. Given ContraFect Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe ContraFect Corporation is more favorable than its peers.
Volatility & Risk
ContraFect Corporation has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, ContraFect Corporation’s peers have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Valuation & Earnings
This table compares ContraFect Corporation and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ContraFect Corporation||N/A||-$28.65 million||-1.92|
|ContraFect Corporation Competitors||$223.74 million||$57.84 million||-0.73|
ContraFect Corporation’s peers have higher revenue and earnings than ContraFect Corporation. ContraFect Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares ContraFect Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ContraFect Corporation Competitors||-917.30%||-187.05%||-24.43%|
ContraFect Corporation peers beat ContraFect Corporation on 7 of the 12 factors compared.
ContraFect Corporation Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.